Analysts’ Viewpoint on Ketoanalogue for Kidney Disease Market Scenario
Kidney diseases, the tenth-leading cause of death, are becoming a global concern. Incidence of chronic kidney diseases and acute renal failure is rising significantly. Dietary supplements in play a crucial role in kidney diseases management. Ketoanalogue supplement is a nutrition supplement often used in chronic kidney diseases.
Alfa ketoanalogue in CKD helps delay the time until dialysis is required to treat uremic symptoms. Slow progression of CKD reduces proteinuria and improves metabolic acidosis and lipid profile. Globally, demand for ketoanalogue supplements, especially for CKD patients, is rising primarily in countries in Asia, such as China and India, due to high incidence rate of kidney diseases and need for effective kidney disease management.
The global ketoanalogue for kidney disease market is consolidated owing to the presence of small number of international and domestic players. The COVID-19 pandemic had a positive effect on the overall ketoanalogue for kidney disease market share. It was difficult to carry out dialysis procedure or regular medical check-up during the COVID-19 pandemic, therefore patients have been looking for medicines that help delay the progress of kidney disease and dialysis process.
Alpha ketoanalogue belongs to a class of drugs called nutritional or dietary supplements. It is widely used in the treatment of kidney disease. Chronic kidney disease (CKD) is a long-term condition, where the kidneys do not function properly. It is usually caused by various conditions such as high blood pressure, diabetes, high cholesterol, kidney infections, kidney inflammation, recurring kidney stones, or an enlarged prostate; and long-term, regular use of certain medicines such as lithium; and non-steroidal anti-inflammatory drugs (NSAIDs).
Dietary factors could affect the progression of chronic kidney disease and its complications. Progression of chronic kidney disease leads to end-stage of renal disease (ESRD), which currently has no cure. Among CKD patients, overnutrition results in hyperphosphatemia, hyperkalemia, sodium/volume overload, and accumulation of toxic metabolites of protein degradation. The current strategy for controlling CKD is relatively conservative and aims to delay the time for dialysis and to relieve symptoms & signs caused by CKD-related comorbidities. Ketosteril is one of the ketoanalogue supplements that could slow down the progression of CKD. Ketoanalogues supplement intervention in pre-ESRD patients with eGFR > 18 could prevent renal function deterioration. Alfa ketoanalogue in CKD helps prevent CKD progression; however, early intervention can also effectively slow down this progression.
The global ketoanalogue for kidney disease market is driven by increase in incidence of kidney disease and rise in usage of ketoanalogue supplement in kidney disease management. Surge in awareness about the importance of nutrition management in kidney diseases is likely to augment the global market.
The burden of various chronic kidney diseases across the globe is expected to rise significantly in the next few years. According to the National Kidney Foundation, around 10% of the global population is affected by chronic kidney disease (CKD), and millions die each year because they do not have access to affordable critical and chronic care products. According to the Centers for Disease Control and Prevention (CDC), a staggering 37 million adults are estimated to have kidney disease in the U.S. Additionally, increase in incidence of chronic diseases associated with the kidneys is another major factor driving the global ketoanalogue for kidney disease market. Diabetes, hypertension, osteoarthritis, chronic obstructive pulmonary disease (COPD), asthma, and depressive disorders are the major chronic diseases associated with the kidneys. Diabetes and hypertension are the major causes of kidney failure. According to the International Diabetes Federation, 422 million people were living with diabetes globally in 2016, and over 10% of the world’s adult population (642 million) is projected to have diabetes by 2040.
Increase in usage of ketoanalogue supplement in the treatment of kidney diseases is likely to drive the global ketoanalogue for kidney disease market size during the forecast period. Dietary protein plays a crucial role in the management of kidney diseases, and low protein diet (LPD) is typically advised to CKD patients to reduce uremic symptoms and slow the advancement of renal dysfunction. Alpha ketoanalogue is a form of essential amino acid. It provides metabolic benefit to the body. Alpha ketoanalogue in CKD is most commonly used as nutrition therapy or dietary supplements. This medicine prevents the unnecessary increase in urea levels in the blood due to the intake of non-essential amino acids in patients with kidney failure.
In terms of application, the chronic kidney disease segment accounted for significant market share in 2021. Chronic kidney disease (CKD) occurs when the kidneys are damaged and cannot filter blood the way they should. The disease is called ‘chronic’ because the damage to the kidneys happens slowly over a long period. This damage can cause wastes to build up in the body. CKD can also cause other health issues. Alpha ketoanalogue in CKD helps slow down the progression of kidney disease, improve the quality of life, and improve calcium & phosphate metabolism. Additionally, increase in incidence of chronic kidney diseases along with associated diseases, such as diabetes and hypertension, is projected to drive the chronic kidney disease segment during the forecast period.
Based on distribution channel, the hospital pharmacies segment is likely to account for major share of the global ketoanalogue for kidney disease market during the forecast period. Prevalence of kidney injury among hospitalized patients is a major factor that fuels the demand for kidney injury treatment at hospitals. Moreover, the number of patients being treated at hospitals is increasing due to favorable reimbursement policies. Therefore, the segment is anticipated to grow at a rapid pace during the forecast period. Rising awareness about ketoanalogue supplements and the trend of utilization of new & improved drugs by patients and physicians are expected to propel the segment.
North America accounted for the largest share of around 42% of the global ketoanalogue for kidney disease market in 2021. The region is likely to be a highly lucrative market during the forecast period. North America's dominance of the global ketoanalogue for kidney disease market is ascribed to increase in incidence of kidney disease in the region. Additionally, high rate of adoption of new technologically advanced products, significant health care expenditure, early availability of advanced technologies, and increase in research activities are projected to augment the ketoanalogue for kidney disease market in North America during the forecast period. The U.S. dominated the market in the region owing to the presence of major market players and increase in the demand for ketoanalogue products in kidney diseases management.
The ketoanalogue for kidney disease market in Asia Pacific is anticipated to grow rapidly during the forecast period due to large patient base in countries, such as India and China, and rise in awareness about kidney disease treatment in the region.
The global ketoanalogue for kidney disease market is consolidated, with a presence of a small number of leading players. Most of the companies are investing significantly in research & development, primarily to develop innovative ketoanalogue supplements. Expansion of product portfolio and mergers & acquisitions are prominent strategies adopted by key players in the global ketoanalogue for kidney disease market. Fresenius Kabi AG, RPG Life Sciences Ltd., La Renon Healthcare Pvt. Ltd., and Ajanta Pharma Limited are the key players operating in the global market.
Each of these players has been profiled in the ketoanalogue for kidney disease market report based on parameters such as company overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 214.7 Mn |
|
Market Forecast Value in 2031 |
More than US$ 409.6 Mn |
|
Growth Rate (CAGR) |
6.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global ketoanalogue for kidney disease market was valued at US$ 214.7 Mn in 2021
The global ketoanalogue for kidney disease market is projected to reach more than US$ 409.6 Mn by 2031
The global ketoanalogue for kidney disease market grew at a CAGR of 7% from 2017 to 2021.
The global ketoanalogue for kidney disease market is anticipated to grow at a CAGR of 6.5% from 2022 to 2031
Increase in incidence of kidney disease and rise in usage of alfa ketoanalogue in CKD management
North America is likely to account for major share of the global ketoanalogue for kidney disease market during the forecast period
Fresenius Kabi AG, RPG Life Sciences Ltd., La Renon Healthcare Pvt. Ltd., and Ajanta Pharma Limited.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ketoanalogue for Kidney Disease Market Forecast
4.5. Global Ketoanalogue for Kidney Disease Market Outlook
5. Market Outlook
5.1. Average Pricing Per Product
5.2. Insights on Effect of Ketoanalogues on Chronic Kidney Disease Deterioration
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ketoanalogue for Kidney Disease Market Analysis and Forecast, by Application
6.1. Introduction
6.2. Global Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
6.3. Global Ketoanalogue for Kidney Disease Market Forecast, by Application
6.3.1. Chronic Kidney Disease
6.3.1.1. Pre-dialysis
6.3.1.2. Dialysis Patients
6.3.2. Acute Renal Failure
6.3.2.1. Pre-renal
6.3.2.2. Post-renal
6.3.3. Others
7. Global Ketoanalogue for Kidney Disease Market Analysis and Forecast, by End-user
7.1. Introduction
7.2. Global Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user
7.3. Global Ketoanalogue for Kidney Disease Market Forecast, by End-user
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ketoanalogue for Kidney Disease Market Analysis, by End-user
8. Global Ketoanalogue for Kidney Disease Market Analysis, by Region
8.1. Global Ketoanalogue for Kidney Disease Market Analysis, by Region
8.2. Global Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ketoanalogue for Kidney Disease Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ketoanalogue for Kidney Disease Market Analysis
9.1. North America Ketoanalogue for Kidney Disease Market Overview
9.2. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ketoanalogue for Kidney Disease Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
9.5. North America Ketoanalogue for Kidney Disease Market Forecast, by Application
9.5.1. Chronic Kidney Disease
9.5.1.1. Pre-dialysis
9.5.1.2. Dialysis Patients
9.5.2. Acute Renal Failure
9.5.2.1. Pre-renal
9.5.2.2. Post-renal
9.5.3. Others
9.6. North America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
9.7. North America Ketoanalogue for Kidney Disease Market Forecast, by End-user
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ketoanalogue for Kidney Disease Market Analysis
10.1. Europe Ketoanalogue for Kidney Disease Market Overview
10.2. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
10.5. Europe Ketoanalogue for Kidney Disease Market Forecast, by Application
10.5.1. Chronic Kidney Disease
10.5.1.1. Pre-dialysis
10.5.1.2. Dialysis Patients
10.5.2. Acute Renal Failure
10.5.2.1. Pre-renal
10.5.2.2. Post-renal
10.5.3. Others
10.6. Europe Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
10.7. Europe Ketoanalogue for Kidney Disease Market Forecast, by End-user
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ketoanalogue for Kidney Disease Market Analysis
11.1. Asia Pacific Ketoanalogue for Kidney Disease Market Overview
11.2. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Taiwan
11.3.6. Rest of Asia Pacific
11.4. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
11.5. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by Application
11.5.1. Chronic Kidney Disease
11.5.1.1. Pre-dialysis
11.5.1.2. Dialysis Patients
11.5.2. Acute Renal Failure
11.5.2.1. Pre-renal
11.5.2.2. Post-renal
11.5.3. Others
11.6. Asia Pacific Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
11.7. Asia Pacific Ketoanalogue for Kidney Disease Market Forecast, by End-user
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ketoanalogue for Kidney Disease Market Analysis
12.1. Latin America Ketoanalogue for Kidney Disease Market Overview
12.2. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
12.5. Latin America Ketoanalogue for Kidney Disease Market Forecast, by Application
12.5.1. Chronic Kidney Disease
12.5.1.1. Pre-dialysis
12.5.1.2. Dialysis Patients
12.5.2. Acute Renal Failure
12.5.2.1. Pre-renal
12.5.2.2. Post-renal;
12.5.3. Others
12.6. Latin America Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
12.7. Latin America Ketoanalogue for Kidney Disease Market Forecast, by End-user
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ketoanalogue for Kidney Disease Market Analysis
13.1. Middle East & Africa Ketoanalogue for Kidney Disease Market Overview
13.2. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by Application
13.5. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by Application
13.5.1. Chronic Kidney Disease
13.5.1.1. Pre-dialysis
13.5.1.2. Dialysis Patients
13.5.2. Acute Renal Failure
13.5.2.1. Pre-renal
13.5.2.2. Post-renal
13.5.3. Others
13.6. Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share and Attractiveness Analysis, by End-user
13.7. Middle East & Africa Ketoanalogue for Kidney Disease Market Forecast, by End-user
13.8. Hospital Pharmacies
13.9. Retail Pharmacies
13.10. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Company Profile
14.2.1. Fresenius Kabi AG
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Product Portfolio
14.2.1.3. Financial Overview
14.2.1.4. Strategic Overview
14.2.1.5. SWOT Analysis
14.2.2. RPG Life Sciences Ltd.
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Product Portfolio
14.2.2.3. Financial Overview
14.2.2.4. Strategic Overview
14.2.2.5. SWOT Analysis
14.2.3. Alniche Life Sciences Pvt. Ltd.
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Product Portfolio
14.2.3.3. Strategic Overview
14.2.3.4. SWOT Analysis
14.2.4. La Renon Healthcare Pvt. Ltd.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Product Portfolio
14.2.4.3. Strategic Overview
14.2.4.4. SWOT Analysis
14.2.5. Steadfast Medishield Pvt. Ltd.
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Product Portfolio
14.2.5.3. Strategic Overview
14.2.5.4. SWOT Analysis
14.2.6. Panacea Biotec
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Product Portfolio
14.2.6.3. Strategic Overview
14.2.6.4. SWOT Analysis
14.2.7. Element, Inc.
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Product Portfolio
14.2.7.3. Strategic Overview
14.2.7.4. SWOT Analysis
14.2.8. Ajanta Pharma Limited
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Product Portfolio
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
14.2.9. Centaur Pharmaceuticals
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Product Portfolio
14.2.9.3. Strategic Overview
14.2.9.4. SWOT Analysis
14.2.10. Genix Lifescience Pvt. Ltd.
14.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.10.2. Product Portfolio
14.2.10.3. Strategic Overview
14.2.10.4. SWOT Analysis
List of Tables
Table 01: Average Pricing Per Product
Table 02: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 04: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 05: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 09: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 10: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 11: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 14: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 15: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 16: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 19: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 20: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 21: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 25: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 26: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 27: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 28: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Chronic Kidney Disease, 2017–2031
Table 30: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by Acute Renal Failure, 2017–2031
Table 31: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 32: Business Overview (Fresenius Kabi AG)
Table 33: Business Overview (RPG Life Sciences Ltd.)
Table 34: Business Overview (Alniche Life Sciences Pvt. Ltd.)
Table 35: Business Overview (La Renon Healthcare Pvt. Ltd.)
Table 36: Business Overview (Steadfast Medishield Pvt. Ltd.)
Table 37: Business Overview (Panacea Biotec)
Table 38: Business Overview (Ajanta Pharma Limited)
Table 39: Business Overview (Centaur Pharmaceuticals)
Table 40: Business Overview (Genix Lifescience Pvt. Ltd.)
Table 41: Business Overview (United Biotech Pvt. Ltd.)
List of Figures
Figure 01: Global Ketoanalogue for Kidney Disease Market Share, by Application
Figure 02: Global Ketoanalogue for Kidney Disease Market Share, by End-user
Figure 03: Global Ketoanalogue for Kidney Disease Market Share, by Region
Figure 04: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 05: Global Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 06: Global Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 07: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Chronic Kidney Disease, 2017–2031
Figure 08: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Acute Renal Failure, 2017–2031
Figure 09: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Others, 2017–2031
Figure 10: Global Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 11: Global Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 12: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 13: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Acute Retail Pharmacies, 2017–2031
Figure 14: Global Ketoanalogue for Kidney Disease Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 15: Global Ketoanalogue for Kidney Disease Market Value Share Analysis, by Region, 2021 and 2031
Figure 16: Global Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Region, 2022–2031
Figure 17: North America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 18: North America Ketoanalogue for Kidney Disease Market Value Share Analysis, by Country, 2021 and 2031
Figure 19: North America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Country, 2022–2031
Figure 20: North America Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 21: North America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 22: North America Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 23: North America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 24: Europe Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 25: Europe Ketoanalogue for Kidney Disease Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 26: Europe Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 27: Europe Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 28: Europe Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 29: Europe Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 30: Europe Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 31: Asia Pacific Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 32: Asia Pacific Ketoanalogue for Kidney Disease Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 33: Asia Pacific Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 34: Asia Pacific Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 35: Asia Pacific Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 36: Asia Pacific Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 37: Asia Pacific Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 38: Latin America Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 39: Latin America Ketoanalogue for Kidney Disease Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 40: Latin America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 41: Latin America Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 42: Latin America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 43: Latin America Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 44: Latin America Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 45: Middle East & Africa Ketoanalogue for Kidney Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 46: Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 47: Middle East & Africa Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 48: Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share Analysis, by Application, 2021 and 2031
Figure 49: Middle East & Africa Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by Application, 2022–2031
Figure 50: Middle East & Africa Ketoanalogue for Kidney Disease Market Value Share Analysis, by End-user, 2021 and 2031
Figure 51: Middle East & Africa Ketoanalogue for Kidney Disease Market Attractiveness Analysis, by End-user, 2022–2031
Figure 52: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2021
Figure 53: Research & Development Expenditure (US$ Mn) and Y-o-Y Growth (%), 2018-2021
Figure 54: Breakdown of Net Sales (%), by Region/Sub-region, 2021
Figure 55: Breakdown of Net Sales (%), by Business Segment, 2021
Figure 56: Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2021
Figure 57: Breakdown of Net Sales (%), by Business Segment, 2021
Figure 58: Revenue (US$ Mn) and Y-o-Y Growth (%), 2019-2022
Figure 59: Research & Development Expenditure (US$ Mn) and Y-o-Y Growth (%), 2019-2022
Figure 60: Breakdown of Net Sales (%), by Region/Sub-region, 2021
Figure 61: Breakdown of Net Sales (%), by Business Segment, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ketoanalogue for Kidney Disease Market
